Remarkably, recent in vivo results support that RN7SL1-containing CAR T cell-derived EV may be transferred to endogenous immune cells and synergize with CAR T cells to enhance their efficacy against tumor cells, even when tumor cells lose CAR antigen expression, by activating the endogenous immune system [140]. The gene discussed is RN7SL1; the disease is neoplasm.